50 closest statements
by meaning · ranked by similarity · 100 per pageMeaning search returns the 50 nearest statements, then applies your filters.
“Our mission is to remain a pioneer in the field of liver diseases, i.e. identify high potential assets to bring them from discovery or early stages up to late development stages, typically the end of Phase 3.”In use 2025 – now·1 sighting·SEC Form 20-F, filed 2025-04-2987% match
“Our mission is to develop life-changing therapies for patients suffering from debilitating liver diseases.”In use 2021 – now·1 sighting·SEC Form 10-K, filed 2021-03-0970% match
“Our mission is to develop and commercialize safe and effective therapies that extend survival and maintain the quality of life for patients with life-threatening cancers and chronic liver diseases.”In use 2004 – now·1 sighting·SEC Form 10-K, filed 2004-12-1369% match
“Our mission is to create long-term stockholder value by acquiring, developing and commercializing innovative products for the treatment of a variety of human diseases that address important unmet medical needs or offer improved, cost-effective alternatives to current methods of treatment.”In use 2014 – now·1 sighting·SEC Form 10-K, filed 2014-03-1168% match
“Our mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients.”In use 2019 – now·1 sighting·SEC Form 10-K, filed 2019-03-0766% match
“Our mission is to improve the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of novel protein degraders.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2466% match
“Our mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the health care industry.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-2766% match
“Our mission is to advance and grow a portfolio of innovative, early-stage oncology assets based on the latest scientific breakthroughs focused on overcoming immune resistance and expanding the addressable patient population.”In use 2023 – now·1 sighting·SEC Form 20-F, filed 2023-07-3166% match
“Our mission is to develop therapeutic products with the potential to address high unmet medical needs by identifying promising clinical-stage candidates and advancing their development to create products that will improve patients’ lives.”In use 2026 – now·1 sighting·SEC Form S-1, filed 2026-08-2166% match
“Our mission is to advance the understanding of fibrosis by building a biology-, chemistry- and screening- based engine to drive drug development across the spectrum of fibrotic diseases.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-0166% match
“Our mission is to expand our portfolio into a wide range of muscle diseases and become a leader in this area by advancing life-transforming therapeutics for patients with serious muscle diseases.”In use 2021 – now·1 sighting·SEC Form 10-K, filed 2021-03-0466% match
“Our mission is to discover and develop a pipeline of EPBs to treat a broad range of diseases and disorders, with an initial focus on cancers with a high unmet medical need.”In use 2022 – now·1 sighting·SEC Form 20-F, filed 2022-04-2666% match
“Our mission is to become a global leader in the treatment of rare diseases through commercializing, developing and acquiring novel rare disease products.”In use 2021 – now·1 sighting·SEC Form 424B4, filed 2021-01-1466% match
“Our mission is to discover and develop novel therapeutic drugs to treat diseases and disorders for which there are no adequate therapies or for which a new drug would represent a significant advancement over the current therapy.”In use 2003 – now·1 sighting·SEC Form 10-K, filed 2003-03-1466% match
“Our mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function to enable patients with these disorders to live fuller and healthier lives.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-04-2366% match
“Our mission is to identify, develop, and, directly or through collaborations, bring to market novel products for the treatment of rare and ultra-rare diseases or conditions.”In use 2019 – now·1 sighting·SEC Form 10-K, filed 2019-03-1465% match
“Our mission is to discover and develop novel therapeutics to address significant medical needs.”In use 2007 – now·1 sighting·SEC Form 10-K, filed 2007-03-1965% match
“Our mission is to leverage unique insights into protein motion to transform the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of small molecule therapies.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2665% match
“Our mission is to maximize the clinical and commercial potential of cabozantinib, and to position us for future growth through our discovery efforts and expansion of our development pipeline.”In use 2019 – now·1 sighting·SEC Form 10-K, filed 2019-02-2265% match
“Our mission is to discover and develop best- and first-in-class medicines for a broad range of difficult-to-treat diseases in collaboration with our partners.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-04-0865% match
“Our mission is to advance novel therapies, leveraging evidence-based innovation, with the potential to transform the lives of people suffering from serious, chronic conditions and unmet medical needs.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-09-2565% match
“Our mission is to discover, develop and commercialize novel and transformative therapies that improve the lives of patients with serious diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-02-2265% match
“Our mission is to build a community and company capable of sustainably discovering, developing and delivering to patients innovative, important new medicines that will make a material difference in their health, well-being and lives.”In use 2009 – now·1 sighting·SEC Form 10-K, filed 2009-03-1365% match
“Our mission is to build a leading, fully integrated global rare disease company using our patient-centric approach to identify and develop life-transforming medicines for the treatment of severe rare diseases.”In use 2023 – now·1 sighting·SEC Form 20-F, filed 2023-04-1965% match
“Our mission is to develop and commercialize novel therapeutics to treat diseases of the eye, with an initial focus on diseases of the back of the eye.”In use 2005 – now·1 sighting·SEC Form 10-K, filed 2005-03-2165% match
“Our mission is to develop novel therapeutics to treat rare, chronic, and serious infectious diseases in areas of high unmet medical need.”In use 2022 – now·1 sighting·SEC Form 424B4, filed 2022-03-2864% match
“Our mission is to improve the lives of patients throughout the world by successfully identifying, developing and commercializing innovative specialty biopharmaceutical products.”In use 2014 – now·1 sighting·SEC Form 10-K, filed 2014-02-2864% match
“Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases.”In use 2026 – now·1 sighting·SEC Form 424B4, filed 2026-05-0164% match
“Our mission is to address a broad range of diseases where chronic inflammation and immune dysfunction are primary drivers of pathology.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-3064% match
“Our mission is to be leaders in Israel’s biopharmaceutical industry, to identify promising drug compounds and creatively drive the development process towards commercialization.”In use 2020 – now·1 sighting·SEC Form 20-F, filed 2020-03-1264% match
“Our mission is to commercialize innovative drug candidates with novel mechanisms of action as well as intellectual property generated from our research activities for neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.”In use 2018 – now·1 sighting·SEC Form 10-K, filed 2018-07-1664% match
“Our mission is to leverage our unique insights into the chromatin regulatory system to pioneer the discovery, development and commercialization of a new class of therapies that transform the lives of patients suffering from a wide spectrum of diseases with high unmet need.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1164% match
“Our mission is to leverage our unique insights into finding and binding cryptic functional pockets on currently intractable human biology-validated protein targets to discover, develop and commercialize small molecule therapies that can transform the lives of patients suffering from devastating cancers and immune disorders.”In use 2021 – now·1 sighting·SEC Form S-1, filed 2021-06-2564% match
“Our mission is to develop and commercialize first-in-class medicines based on novel targets to improve patients’ lives.”In use 2022 – now·1 sighting·SEC Form 20-F, filed 2022-03-2464% match
“Our mission is to identify, acquire, and accelerate the development and commercialization of medicines that we believe have the potential to offer clinically meaningful, differentiated benefits to patients.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-2864% match
“Our mission is to create value for 35 Table of Contents patients, caregivers, employees and stockholders by discovering, developing and commercializing novel medicines that save and improve lives.”In use 2006 – now·1 sighting·SEC Form 10-K, filed 2006-03-1064% match
“Our mission is to develop and commercialize therapies with the potential to transform the lives of patients and their families living with rare diseases.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-0164% match
“Our mission is to discover and develop broadly accessible oral therapeutics to treat a wide range of chronic diseases with unmet medical need through advancements in structure-based drug discovery and computational chemistry.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2664% match
“Our mission is to offer an ecosystem of innovative discovery and translational research solutions that enable our customers to map the universe of biology and conduct scientific exploration that may lead to new therapies to improve the human condition.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-02-2864% match
“Our mission is to leverage our existing and expanding network of academic and industry leaders and investors, including venture capital and private equity, in major healthcare markets globally to identify, lead and support the growth of our subsidiaries and subsidiary candidates based on innovative research.”In use 2025 – now·1 sighting·SEC Form S-1/A, filed 2025-06-1064% match
“Our mission is to target cancer and transform lives through the development of innovative cancer treatments.”In use 2005 – now·1 sighting·SEC Form 10-K, filed 2005-03-1663% match
“Our mission is to enable the rapid development of innovative therapeutics by pushing the frontiers of drug discovery technologies.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0463% match
“Our mission is to develop novel therapies by utilizing our disease-agnostic platform to address areas of high unmet medical need, initially in cancer and neurologic diseases.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-1063% match
“Our mission is to bring the unserved rare disease patients the solutions they need through our fully integrated and ongoing clinical development and commercialization expertise.Our core values enable our mission and create a clear pathway forward to meet our strategic goals and objectives.”In use 2024 – now·1 sighting·SEC Form 20-F, filed 2024-04-0463% match
“Our mission is to continually apply our scientific research to the more effective management of zoonotic diseases and, in so doing, realize the commercial potential of our molecular biotechnologies.”In use 2023 – now·1 sighting·SEC Form 10-K/A, filed 2023-02-0163% match
“Our mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest unmet medical need – aggressive cancers where current therapies are inadequate.”In use 2016 – now·1 sighting·SEC Form 10-K, filed 2016-02-2963% match
“Our mission is to improve the lives of patients who suffer from rare diseases for which there are limited or no available treatments, with an initial therapeutic focus on Cirrhosis ascites, patients suffering from AIDS, Cancer and chronic pain, nausea and discomfort associated with chemotherapy and neuropathy.”In use 2017 – now·1 sighting·SEC Form 10-K, filed 2017-11-0663% match
“Our mission is to become a leading global, fully integrated biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies to address global unmet medical needs primarily in hematological malignancies.”In use 2025 – now·1 sighting·SEC Form 424B4, filed 2025-01-2463% match
“Our mission is to enhance disease diagnosis by applying cutting-edge genetic diagnostic technologies, enabling earlier and more accurate detection for timely and improved treatment.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-3163% match
“Our mission is to become the leading company in precision genetic medicines by discovering, developing, manufacturing, and ultimately commercializing a new class of medicines through our proprietary base editing technology, with the goal of providing life-long cures to patients suffering from serious diseases.”In use 2020 – now·1 sighting·SEC Form 424B4, filed 2020-10-0163% match
Showing 1–50 of 50